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 Patient: Male, 48
 Final Diagnosis: Adrenal oncocytic carcinoma
 Symptoms: Asymptomatic
 Medication: —
 Clinical Procedure: Transabdominal laparoscopic right adrenalectomy
 Specialty: Surgery
 Objective: Rare disease
 Background: Adrenocortical oncocytic neoplasms (AONs) are extremely rare tumors. AONs are classified as: oncocytoma 
(AO), oncocytic neoplasm of uncertain malignant potential (AONUMP), and oncocytic carcinoma (AOC). Among 
the 162 reported cases of AONs in the literature, 30 cases were classified as malignant. Adrenalectomy is the 
treatment of choice for AON.
 Case Report: We report the case of a 48-year-old man with a primitive 12-cm mass affecting the right adrenal gland, detect-
ed by ultrasonography during follow-up for alcoholic liver cirrhosis. Computed tomography (CT) scan and mag-
netic resonance imaging (MRI) showed a mass of the right adrenal gland compressing the inferior vena cava 
(IVC) and dislocating the right lobe of the liver, with no invasion of kidney, liver, or IVC. Preoperative blood tests 
showed mild transaminase increase. Laparoscopic right adrenalectomy with lateral transperitoneal approach 
was performed. The postoperative course was uneventful. The lesion was diagnosed as a primitive adrenal on-
cocytic carcinoma (AOC). No recurrence was evidenced during 24-month follow-up.
 Conclusions: Although AONs are very rare, they must be considered in the differential diagnosis of adrenal masses due to 
their prognostic difference compared to non-oncocytic tumors. AOCs are a rare presentation of AONs. Only 30 
cases are described in the literature. Laparotomic adrenalectomy is the treatment of choice for AOC. We report 
the first case of laparoscopic lateral trans-abdominal adrenalectomy for a voluminous AOC (120×95×110 mm) 
and we review the literature regarding AOCs. Laparoscopy in experienced hands is safe and effective for the 
treatment of AONs. Despite the rarity of AOC, a case series should be performed to confirm the results of our 
case report.
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Background
Oncocytic neoplasms (ONs), or oncocytomas, are tumors that 
are mainly composed of oncocytic cells. Oncocytic cells were 
described for the first time by Hamperl in 1931 as large, high-
ly eosinophilic, granular cells with pyknotic nucleus, typically 
associated with a Hurtle cell tumor of the thyroid gland [1,2]. 
The cytoplasmic granularity is characterized by a striking ac-
cumulation of mitochondria, as demonstrated through elec-
tron microscopy in 1986, that can occupy up to 60% of the cy-
toplasm volume [3,4]. ONs arise in various organs, including 
kidney, thyroid, pancreas, parathyroid, salivary, lacrimal, pitu-
itary glands, paraganglia, respiratory tract, paranasal sinus-
es, pleura, liver, pancreatobiliary system, stomach, colon, rec-
tum, central nervous system, female and male genital tracts, 
skin, and soft tissues [5–21]. ONs arising from adrenal glands 
are extremely rare and were first described by Kakimoto et al. 
in 1986 [22]. Adrenocortical oncocytic neoplasms (AONs) are 
usually observed to be non-functional and mostly benign tu-
mors. AONs are classified as: oncocytoma (AO), oncocytic neo-
plasm of uncertain malignant potential (AONUMP), and onco-
cytic carcinoma (AOC) [23]. Since the first description, a total 
of 162 cases of AONs have been reported, with 30 cases de-
scribed as AOC [23,24]. Tumor size is considered to be a prac-
tical sign to differentiate benign from malign disease in adre-
nocortical carcinomas (diameter <4–5 cm suggests a benign 
mass). However, in case of AONs, the size of the mass and the 
imaging findings (through abdominal CT scan and MRI) are not 
pathognomonic or related to malignancy [24]. Because AONs 
are non-functional, differential diagnosis should be done with 
indeterminate adrenal tumors (incidentalomas). AONs are usu-
ally detected as a large mass with an average diameter of 8 cm 
(range 2–20 cm) [25]. Adrenalectomy is the treatment of choice 
for AONs. Surgical approaches to adrenal gland include laparot-
omy, combined thoraco-abdominal access, retroperitoneal pos-
terior access, laparoscopy, and robotic surgery [27]. Since the 
first successfully laparoscopic adrenalectomy (LA) performed 
by Gagner in 1991 [28], the lateral trans-abdominal approach 
has become the most common therapeutic strategy for adrenal 
neoplasms [29–34]. To the best of our knowledge, this is the 
first case report of laparoscopic lateral trans-abdominal adre-
nalectomy for a large AOC (12 cm) (Supplementary Video 1).
Case Report
A 48-year-old man was admitted to our Surgical Department 
for a primitive 12-cm mass affecting the right adrenal gland. 
The mass was detected by abdominal ultrasound during an-
nual follow-up for liver cirrhosis (Child-Turcotte-Pugh score A). 
The patient was submitted to contrast-enhanced abdominal CT 
scan in our hospital (Figure 1) and contrast-enhanced abdomi-
nal MRI in another institute with evidence of a capsulated solid 
adrenal mass (diameters: 120×95×110 mm) with an irregular 
vascularization pattern, compressing the inferior vena cava, 
and dislocating the right lobe of the liver. A cleavage plane be-
tween the liver and the right kidney was evident with no lym-
phonodal or any other intra-abdominal neoplastic involvement. 
Preoperative laboratory tests (including cortisol, 17-ketoste-
roids, and 17-hydrocorticosteroids serum levels), dexametha-
sone test, complete blood count test results, and renal function 
were all normal, while liver enzyme levels were mildly elevat-
ed. The patient was a non-smoker, chronic alcohol abuser (1–2 
bottles of wine per day). No endocrinopathy sign or symptoms 
were identified. Therefore, a non-functional adrenal mass was 
diagnosed, but no preoperative US- or CT-guided fine-needle 
aspiration cytology was performed because of the wide size 
of the mass, which made surgery mandatory. Considering the 
presence of a clear cleavage plane between the adrenal lesion 
and the liver, the kidney, and the surrounding vascular struc-
tures, and the absence of evident lymphonodal or other vis-
ceral involvement, a laparoscopic approach was attempted. In 
fact, despite the size of the lesion, no signs of malignancy or 
infiltration were found preoperatively, thus making the lap-
aroscopic approach laborious but feasible and oncologically 
radical in skilled hands. The patient underwent lateral trans-
abdominal laparoscopic right adrenalectomy with a standard 
4-trocars technique in left lateral decubitus position. During 
the operation, the IVC was easily dissociated from the lesion, 
and en-bloc right adrenalectomy was completed with no cap-
sule rupture. Extraction was performed in toto. No major bleed-
ing and no major intraoperative complications were encoun-
tered. The patient remained hemodynamically stable during the 
procedure. The postoperative course was uneventful and the 
patient was discharged on the 5th postoperative day in good 
condition. Macroscopic examination of the specimen revealed 
Figure 1.  Contrast-enhanced abdominal CT scan axial image 
showing the right adrenal mass (white arrow), 
the hepatic dislocation, and the inferior vena cava 
compression (white arrow head).
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a solid mass, measuring 123×98×113 mm, weighting 300 g, 
with several necrotic areas. Microscopic examination report-
ed a primitive oncocytic adrenal carcinoma (Figure 2). Several 
atypical mitotic figures and high mitotic index (10/50 HPFs) 
were observed, together with diffuse pattern of growth and 
venous invasion. The patient’s Weiss score was 5 and, accord-
ing to modified Weiss score, the patient had an AOC. The tu-
mor cells were immunopositive for vimentin and presented 
typical oncocytic architecture. KI-67 and MIB1 rate was 20%. 
The patient was not eligible for therapy with mitotane (RS)-1-
chloro-2-[2,2-dichloro-1-(4-chlorophenyl)-ethyl]-benzene due 
to the chronic liver disease. He was submitted to follow-up 
with an abdominal CT scan performed every 6 months for the 
first year and once during the second year. No recurrence was 
evidenced during 24-month follow-up.
Discussion
Adrenocortical carcinoma (AC) is a rare and aggressive tumor 
of the adrenal cortex that accounts for 0.2% of all malignancies 
(prevalence 1–2 cases per million) [35]. AONs are an extreme-
ly rare subtype of AC, with 162 cases reported in the literature 
since the first description in 1986 [18]. AONs are usually inci-
dental [36–41] with only 17% cases described as functional [42]. 
AONs do not have a precise peak incidence, with a mean age 
at diagnose of 47 years (range 27–72 years) [25]. AONs occurs 
more frequently in females (F/M: 2.5/1) and on the left side 
(L/R: 3.5/1) [25]. AONs are located in the adrenal cortex, with 
only 1 case reported within the adrenal medulla and 1 with-
in heterotopic adrenal tissue [43,44]. To date, no specific risk 
factors have been identified and the pathogenesis of oncocy-
tosis is still unclear. Krech et al. [45] demonstrated the role of 
N-nitrosomorpholine, an airborne contaminant, as a chemical 
inducer of oncocytosis in renal tissue of Sprague-Dawley rats, 
managing to generate an in vivo model resembling human on-
cocytoma. However, no further experimental studies have been 
reported using this rat model. Oncocytes have characteristic 
severe mitochondrial anomalies: mitochondria are numerous 
with an excess of cristae mitochondriales. The shape varies 
from round and oval to extremely elongated, slender, or cup-
shaped, often piled up to form complex bodies; mitochondria 
can rarely form large ramifying organelles [45]. Some authors 
reported a role of mitochondrial genome mutation in oncocy-
tosis pathogenesis [46,47]. Duregon et al. analyzed the pres-
ence of the mtDNA 4977 bp “common deletion”, present in 
50% of AOCs, as a potential pathogenetic interest, but to date, 
it has no practical diagnostic value [47]. Macroscopically, AOCs 
are large, rounded, encapsulated, brown-yellow, and well-cir-
cumscribed masses with an average diameter of 8 cm (range 
2–20 cm) and a thin rim of normal adrenal gland. The mean 
AOCs weight is 281 g (range 8–865 g) [48]. Microscopically, 
AOCs can appear with solid, trabecular, tubular, or papillary 
patterns. AOCs are characterized by: diffuse proliferation of 
polygonal cells with abundant granular and eosinophilic cyto-
plasm, large nuclei and prominent nucleoli, occasional mono-
nuclear and binucleated giant cells, extracapsular extension 
with blood vessel invasion and necrosis, and variable atyp-
ia and mitotic figures [49]. The immunophenotypic profile of 
AONs is diffuse positivity for vimentin, melan-A, synaptophy-
sin, and alpha-inhibin [50–52]. AONs are classified as oncocy-
toma (AO), oncocytic neoplasm of uncertain malignant poten-
tial (AONUMP) [48], and oncocytic carcinoma (AOC) [19,53–56]. 
The Weiss Criteria are considered the standard tool for diagno-
sis of AC [57]. This system considers 9 criteria (nuclear grade 
III–IV; mitotic rate >5/50 HPFs; atypical mitotic figures; eosin-
ophilic tumor cell cytoplasm (>75% of tumor cells); diffuse ar-
chitecture (>33% of tumor); necrosis; venous invasion, sinu-
soidal and capsular invasion) (Table 1). A 1-point score is given 
to each parameter. Malignancy can be suspected when 4 or 
more of the 9 criteria are met. However, care should be tak-
en in applying these criteria during pathological evaluation of 
Figure 2.  Adrenal cortical oncocytic carcinoma (left side area 
with the white star – 10×).
Weiss criteria Score
High nuclear grade (III–IV) 1
Atypical mitotic figures 1
Mitotic rate >5/50 HPF 1
Eosinophilic tumor cell cytoplasm 
(>75% of tumor cells)
1
Diffuse architecture (>33% of tumor) 1
Necrosis 1
Venous invasion 1
Sinusoidal invasion (no smooth muscle in 
wall)
1
Capsular invasion 1
Table 1. Weiss criteria.
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the rare and peculiar AOC. Bisceglia et al. proposed a review of 
the Weiss Criteria, proposing major and minor criteria for AOC 
diagnosis (Table 2) [58]. AOC is characterized by the presence 
of 1 of the following 3 (major criteria): mitotic rate >5/50 HPF, 
atypical mitotic figures, and/or venous invasion. AONUMP is 
characterized by at least 1 of the following 4 (minor criteria): 
size >10 cm and/or weight >200 mg, necrosis, capsular inva-
sion, and/or sinusoidal invasion. AO is characterized by the ab-
sence of both major and minor criteria. Several molecular and 
biological studies have been performed on AC to characterize 
the malignancy and establish new ocnological parameters [59–
64]. However, no established premalignant condition has been 
documented in the human adrenal cortex and no adrenocorti-
cal adenoma to AC transition has been described. Furthermore, 
there are very few cases of AOC described in the literature, 
with few molecular studies. In addition, ACs are markedly het-
erogeneous morphologically and functionally, even within the 
same tumor [65]. Among several molecular and/or cytological 
markers that may contribute to the differential diagnosis of 
adrenocortical carcinoma, the cell proliferation markers, such 
as Ki-67 and topoisomerase, and oncoprotein p53, can be of 
most value [59–64,66–69]. Unfortunately, the role of either Ki-
67 or p53 as biomarkers remains uncertain due to the avail-
ability of so few of these tumors [70,71]. However, according 
to Mearini et al., MIB1 and Ki- 67 are of practical value in or-
der to achieve a differential diagnosis between benign mass 
and adenocarcinoma [25].
The size and the function of the lesion are considered the 
most important factors in the diagnosis of an adrenal mass. 
In a report on 887 patients who had adrenal incidentalomas, 
a diameter greater than 4 cm was shown to have a 90% sen-
sitivity for the detection of AC, but a low specificity (only 24% 
of the lesions were malignant) [72]. Increase in size over time 
is another indication for surgery. Generally, resection is rec-
ommended for adrenal masses > 6 cm. Biochemical analyses 
should be undertaken to rule out the presence of a primary 
functioning mass, which requires resection despite the size.
Imaging has a major role during differential diagnosis between 
AC, included AONs, from adrenal adenomas. Fat concentration 
may be used as a tool to differentiate between benign and ma-
lignant adrenal lesions: with the first being lipid-rich. The CT 
criteria for the diagnosis of adrenal adenoma are unenhanced 
attenuation of 10 or fewer HUs [73] and absence of necrotic 
or cystic areas, which can be seen in some malignant lesions 
and adrenal cysts [74]. However, it has not been demonstrat-
ed to be a characteristic imaging for AON; therefore, CT imag-
ing findings are generally nonspecific [75–77]. MRI with chem-
ical shift subtraction [78] provides a high confidence level in 
distinguishing adrenal adenomas from other disease [79,80]. 
However, MRI is considered not specific for AON detection [81].
Although the use of contrast-enhanced ultrasound has shown 
an excellent sensitivity and specificity in the differential diag-
nosis between benign and malignant adrenal mass, no typi-
cal pattern has been described for AONs [82].
Fine-needle aspiration cytology and open biopsy are help-
ful during perioperative diagnosis of AC; however, they are 
not able to specifically characterize and define AONs [83,84].
Adrenalectomy is the treatment of choice for AON. Different 
surgical approaches are available to treat adrenal masses. The 
surgical approach choice depends on several parameters: tu-
mor size, malignancy, patient condition, and surgical experi-
ence [85]. The surgical approach to adrenal gland includes lap-
arotomy, combined thoraco-abdominal access, retroperitoneal 
posterior access, laparoscopy, and robotic surgery [86]. Since 
the first successfully laparoscopic adrenalectomy (LA) per-
formed by Gagner in 1991 [28], the lateral trans-abdominal 
approach has become the most common therapeutic strate-
gy for adrenal neoplasm [28–34]. LA is associated with low-
er postoperative pain, reduced ileus, shorter hospitalization, 
earlier return to work, and a better cosmetic result, guaran-
tying a lower morbidity (5–20%) and mortality rate (below 
0.5%) compared to open adrenalectomy [25,31,34]. In con-
trast, open adrenalectomy is associated with higher mortality 
(2–4%) and morbidity rates (bleeding, pulmonary and cardiac 
complications, pulmonary thromboembolism, and wound in-
fections) and is reserved worldwide only for large tumors (di-
ameter >6 cm) and primary malignancies, based on the rad-
icality of resection, minor tumor local recurrence, and major 
survival [27,87,88]. The mainstay of the surgical procedure is 
to perform a complete resection of the adrenal gland without 
disruption of the adrenal capsule. Therefore, the presence of 
AON subtypes Criteria
AOC One of the following 3 (major criteria)
Mitotic rate >5/50 HPF 
Atypical mitotic figures
Venous Invasion
AONUMP
At least one of the following 4 (minor 
criteria)
Size >10 cm and/or weight >200 g
Necrosis
Capsular invasion
Sinusoidal invasion
AO Lack of major and minor criteria
Table 2. Modified Weiss criteria for AON.
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capsular or vascular invasion, infiltration of surrounding tis-
sues, and lymphonodal involvement represent the major con-
traindications to LA. Several different laparoscopic techniques 
have been proposed and are currently used for the resection 
of adrenal tumors [27]. Each technique has its own advantag-
es and disadvantages. Lateral trans-abdominal adrenalecto-
my (LTA) is the most common adrenalectomy technique used 
by general surgeons. Compared with the retroperitoneal ap-
proach, LTA provides more working space, which can be ben-
eficial for large tumors and morbidly obese patients. In addi-
tion, the lateral decubitus position used during this approach 
enables excellent exposure of the adrenal gland because of 
the effect of gravity on the abdominal organs. Posterior ret-
roperitoneoscopic adrenalectomy (PRA) [27] is characterized 
by enhanced visualization following the use of higher insuf-
flation pressures in the retroperitoneal cavity, as well as di-
rect access to the adrenal gland (avoiding the intra-abdominal 
cavity), making it attractive in case of prior abdominal surgery. 
Additionally, the prone position facilitates equal access to the 
right and left sides, allowing bilateral procedures without the 
need for patient intra-operative repositioning. The disadvan-
tages include lack of access to the intra-abdominal cavity for 
evaluation, difficult removal of large tumors, and increased dif-
ficulty with increasing body mass index (BMI). Anterior trans-
abdominal adrenalectomy [27] is a sub-mesocolic approach 
and is the least common technique used for adrenalectomy; 
its main appeal is the conventional abdominal laparoscopic 
view, familiar to all general surgeons. However, the operating 
times are generally longer, and more ports are needed for a 
successful operation. Lateral retroperitoneoscopic adrenalec-
tomy (LPA) [27] is the most common technique used by uro-
logic surgeons for adrenalectomy, likely due to their familiarity 
with the anatomy of laparoscopic nephrectomy. Similar to PRA, 
LPA is advocated for patients with prior abdominal surgery.
AONs are very rare lesions, with 162 reported cases in the lit-
erature and only 30 cases reported as AOCs. To the best of 
our knowledge, this is the first reported case of laparoscop-
ic adrenalectomy for a voluminous AOC (120×95×110 mm). 
Following CT and MRI imaging, a well-encapsulated tumor, 
with no evidence of invasion of the surrounding tissues and 
no regional adenopathy, was detected. In our case, laparo-
scopic approach with 4-trocar placement was chosen. The pa-
tient was positioned in left lateral decubitus position at a 60° 
angle. The table was flexed for space widening between the 
12th rib and the iliac crest. Four ports were used. The proce-
dural steps included: mobilization of the right triangular liga-
ment of the liver, incision between the retroperitoneal attach-
ments of the right hepatic lobe and the lateral border of the 
inferior vena cava (IVC), dissection of the lateral edge of the 
IVC, and taking of the right adrenal vein at the takeoff from 
the IVC. Mobilization of the gland was performed with an in-
ferior-to-superior and medial-to-lateral approach. The surgi-
cal procedure was safe and effective and the postoperative 
period was uneventful. The 24-month follow up was nega-
tive for disease recurrence. Macroscopic examination of the 
specimen revealed a solid mass weighting 300 g, with several 
necrotic areas. Microscopic examination showed a primitive 
oncocytic adrenal carcinoma. Several atypical mitotic figures 
and high mitotic index (10/50 HPFs) were observed, togeth-
er with diffuse pattern of growth and venous invasion. The 
specimen was evaluated with a final Weiss score of 5 (necro-
sis, high mitotic rate >5/50 HPF, atypical mitotic figures, dif-
fuse architecture, and venous invasion). According to modi-
fied Weiss score, an AOC was diagnosed (mitotic rate >5/50 
HPF, atypical mitotic figures, and venous invasion). The tumor 
cells were immunopositive for vimentin and presented typical 
oncocytic architecture. In our case, the neoplastic cells had a 
KI-67 and MIB1 rate of 20%.
In 2013, the Society of American Gastrointestinal and 
Endoscopic Surgeons (SAGES) presented guidelines for mini-
mally invasive treatment of adrenal pathology [27]. However, 
these guidelines are limited to a retrospective analysis of pub-
lished case series, with no specificity for AONs. In our case, 
we performed an effective laparoscopic approach to a volumi-
nous AOC, with 24-month follow-up negative for recurrence. 
In light of our result, a prospective multicentric observational 
study should be performed to better define the aims and lim-
its of minimally invasive surgery for AON. Due to the scarci-
ty of cases, it is difficult to establish precise guidelines on the 
management of adrenal oncocytic neoplasms. Our case report 
is fully compliant with SCARE criteria [89].
Conclusions
Adrenocortical oncocytic tumors must be taken into ac-
count in the differential diagnosis of adrenal masses due 
to their different prognosis compared to non-oncocytic tu-
mors. Adrenocortical oncocytic carcinoma are a rare presen-
tation of AONs. Only 30 cases are described in the literature. 
Laparotomic adrenalectomy is the treatment of choice for 
AOC. We report the first case of laparoscopic lateral trans-ab-
dominal adrenalectomy for AOC, despite the large size of the 
mass (120×95×110 mm). Laparoscopy performed by an expe-
rienced surgeon is safe and effective for AOC. Despite the rar-
ity of AOC, a case series should be performed to confirm the 
results of our case report.
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